In cancer, abnormally (de)activated signaling pathways such as mTOR/PI3K-Akt and NFκB signaling stimulate tumor cells to proliferate aggressively, metastasize, and become even more resilient to therapy [54,55,56,57,58]. Here, NFKB1 is linked to cancer.